2014

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aveo Pharmaceuticals, Inc.

NEW YORK, May 3, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Aveo Pharmaceuticals, Inc. ("Aveo" or the "Company") (NasdaqGS: Aveo).  The investigation focuses on whether the Company and its executives violated federal securities laws.

On May 2, 2013, shares of Aveo Pharmaceuticals plunged almost 50 percent after the company said a Food and Drug Administration ("FDA") panel recommended its drug Tivopath not be approved as a treatment for advanced kidney cancer.  The FDA advisory panel rejected approval for AVEO's drug tivozanib by a vote of 13-1; Aveo hadn't demonstrated the medicine's benefits outweigh the risks.

If you are aware of any facts relating to this investigation, or purchased shares of Aveo, you can assist this investigation by contacting Peretz Bronstein of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein 212-697-6484
info@bgandg.com

SOURCE Bronstein, Gewirtz & Grossman, LLC




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.